These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

44 related items for PubMed ID: 19565909

  • 1. Chemosensitization of tumor cells: inactivation of nuclear factor-kappa B associated with chemosensitivity in melanoma cells after combination treatment with E2F-1 and doxorubicin.
    Hao H, Zhou HS, McMasters KM.
    Methods Mol Biol; 2009; 542():301-13. PubMed ID: 19565909
    [Abstract] [Full Text] [Related]

  • 2. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.
    Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V, Weber O, Stiewe T, Ziegelbauer K, Schön MP.
    J Natl Cancer Inst; 2008 Jun 18; 100(12):862-75. PubMed ID: 18544741
    [Abstract] [Full Text] [Related]

  • 3. Alteration of gene expression in melanoma cells following combined treatment with E2F-1 and doxorubicin.
    Hao H, Dong YB, Bowling MT, Zhou HS, McMasters KM.
    Anticancer Res; 2006 Jun 18; 26(3A):1947-56. PubMed ID: 16827129
    [Abstract] [Full Text] [Related]

  • 4. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.
    Marín YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH.
    Melanoma Res; 2007 Oct 18; 17(5):274-83. PubMed ID: 17885582
    [Abstract] [Full Text] [Related]

  • 5. Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor.
    Pletz N, Schön M, Ziegelbauer K, Emmert S, Liu N, Dobbelstein M, Schön MP.
    Exp Dermatol; 2012 Apr 18; 21(4):301-4. PubMed ID: 22320445
    [Abstract] [Full Text] [Related]

  • 6. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.
    Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A.
    Mol Pharmacol; 2008 Aug 18; 74(2):476-84. PubMed ID: 18463201
    [Abstract] [Full Text] [Related]

  • 7. Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells.
    Wozniak M, Szulawska-Mroczek A, Hartman ML, Nejc D, Czyz M.
    Anticancer Res; 2013 Aug 18; 33(8):3205-12. PubMed ID: 23898080
    [Abstract] [Full Text] [Related]

  • 8. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation.
    Rödel F, Hantschel M, Hildebrandt G, Schultze-Mosgau S, Rödel C, Herrmann M, Sauer R, Voll RE.
    Int J Radiat Biol; 2004 Feb 18; 80(2):115-23. PubMed ID: 15164793
    [Abstract] [Full Text] [Related]

  • 9. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells.
    Ho WC, Dickson KM, Barker PA.
    Cancer Res; 2005 May 15; 65(10):4273-81. PubMed ID: 15899819
    [Abstract] [Full Text] [Related]

  • 10. NF-kappa B-mediated chemoresistance in breast cancer cells.
    Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS.
    Surgery; 2001 Aug 15; 130(2):143-50. PubMed ID: 11490342
    [Abstract] [Full Text] [Related]

  • 11. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.
    Tse AK, Wan CK, Shen XL, Yang M, Fong WF.
    Biochem Pharmacol; 2005 Nov 15; 70(10):1443-57. PubMed ID: 16181613
    [Abstract] [Full Text] [Related]

  • 12. Selective activation of NF-kappaB and E2F by low concentration of arsenite in U937 human monocytic leukemia cells.
    Yamamoto M, Hirano S, Vogel CF, Cui X, Matsumura F.
    J Biochem Mol Toxicol; 2008 Nov 15; 22(2):136-46. PubMed ID: 18418899
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 18. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA.
    Clin Cancer Res; 2005 Dec 01; 11(23):8398-402. PubMed ID: 16322301
    [Abstract] [Full Text] [Related]

  • 19. Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis.
    Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY.
    Oncogene; 2004 Nov 18; 23(54):8731-42. PubMed ID: 15480428
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.